Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.02+0.02 (+0.67%)
Close on Nov 17, 2026Market cap $70.84MP/E –Yield –
Coya Therapeutics cash
Cash and short-term investments held at the end of each period.
Coya Therapeutics's cash was $35.80M at Sep 30, 2026. For fiscal 2025 it was $46.82M, up 22.1% from the year before. The highest annual figure on record is $46.82M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.82M | +22.1% |
| FY2024 | Dec 31, 2024 | $38.34M | +17.5% |
| FY2023 | Dec 31, 2023 | $32.63M | +449.9% |
| FY2022 | Dec 31, 2022 | $5.93M | +36.7% |
| FY2021 | Dec 31, 2021 | $4.34M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $35.80M | +27.3% |
| Q2 FY2026 | Jun 30, 2026 | $43.18M | +45.1% |
| Q1 FY2026 | Mar 31, 2026 | $50.72M | +42.8% |
| Q4 FY2025 | Dec 31, 2025 | $46.82M | +22.1% |
| Q3 FY2025 | Sep 30, 2025 | $28.13M | -9.4% |
| Q2 FY2025 | Jun 30, 2025 | $29.76M | -18.6% |
| Q1 FY2025 | Mar 31, 2025 | $35.53M | -1.3% |
| Q4 FY2024 | Dec 31, 2024 | $38.34M | +17.5% |
| Q3 FY2024 | Sep 30, 2024 | $31.06M | +185.3% |
| Q2 FY2024 | Jun 30, 2024 | $36.58M | +179.1% |
| Q1 FY2024 | Mar 31, 2024 | $35.99M | +120.5% |
| Q4 FY2023 | Dec 31, 2023 | $32.63M | +449.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.89M | +150.8% |
| Q2 FY2023 | Jun 30, 2023 | $13.10M | – |
| Q1 FY2023 | Mar 31, 2023 | $16.32M | – |
| Q4 FY2022 | Dec 31, 2022 | $5.93M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.34M | – |
See a number that looks wrong?